These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31811076)

  • 1. Neuropathological Validation of Cerebrospinal Fluid Biomarkers in Neurodegenerative Diseases.
    Irwin DJ
    J Appl Lab Med; 2019 Dec; ():. PubMed ID: 31811076
    [No Abstract]   [Full Text] [Related]  

  • 2. Autopsy-diagnosed neurodegenerative dementia cases support the use of cerebrospinal fluid protein biomarkers in the diagnostic work-up.
    Bruzova M; Rusina R; Stejskalova Z; Matej R
    Sci Rep; 2021 May; 11(1):10837. PubMed ID: 34035398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteinase-activated receptor 2 and disease biomarkers in cerebrospinal fluid in cases with autopsy-confirmed prion diseases and other neurodegenerative diseases.
    Rohan Z; Smetakova M; Kukal J; Rusina R; Matej R
    BMC Neurol; 2015 Mar; 15():50. PubMed ID: 25886404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.
    Toledo JB; Brettschneider J; Grossman M; Arnold SE; Hu WT; Xie SX; Lee VM; Shaw LM; Trojanowski JQ
    Acta Neuropathol; 2012 Jul; 124(1):23-35. PubMed ID: 22526019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of biomarkers across different neurodegenerative diseases.
    Ehrenberg AJ; Khatun A; Coomans E; Betts MJ; Capraro F; Thijssen EH; Senkevich K; Bharucha T; Jafarpour M; Young PNE; Jagust W; Carter SF; Lashley T; Grinberg LT; Pereira JB; Mattsson-Carlgren N; Ashton NJ; Hanrieder J; Zetterberg H; Schöll M; Paterson RW
    Alzheimers Res Ther; 2020 May; 12(1):56. PubMed ID: 32404143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolites and Biomarker Compounds of Neurodegenerative Diseases in Cerebrospinal Fluid.
    Wakamatsu K; Chiba Y; Murakami R; Miyai Y; Matsumoto K; Kamada M; Nonaka W; Uemura N; Yanase K; Ueno M
    Metabolites; 2022 Apr; 12(4):. PubMed ID: 35448530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal Fluid and MRI Biomarkers in Neurodegenerative Diseases: A Retrospective Memory Clinic-Based Study.
    Kaipainen A; Jääskeläinen O; Liu Y; Haapalinna F; Nykänen N; Vanninen R; Koivisto AM; Julkunen V; Remes AM; Herukka SK
    J Alzheimers Dis; 2020; 75(3):751-765. PubMed ID: 32310181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders.
    Ashton NJ; Hye A; Rajkumar AP; Leuzy A; Snowden S; Suárez-Calvet M; Karikari TK; Schöll M; La Joie R; Rabinovici GD; Höglund K; Ballard C; Hortobágyi T; Svenningsson P; Blennow K; Zetterberg H; Aarsland D
    Nat Rev Neurol; 2020 May; 16(5):265-284. PubMed ID: 32322100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration.
    Miller AM; Rutkowska A; Bahl JM; Herukka SK; Koel-Simmelink MJ; Kruse N; Mollenhauer B; Siloaho M; Skinningsrud A; Zetterberg H; Teunissen CE; Lawlor BA
    Bioanalysis; 2016 Nov; 8(21):2243-2254. PubMed ID: 27684648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders.
    Marques TM; Van Rumund A; Kuiperij HB; Verbeek MM
    Handb Clin Neurol; 2017; 146():99-113. PubMed ID: 29110782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.
    Wilcock D; Jicha G; Blacker D; Albert MS; D'Orazio LM; Elahi FM; Fornage M; Hinman JD; Knoefel J; Kramer J; Kryscio RJ; Lamar M; Moghekar A; Prestopnik J; Ringman JM; Rosenberg G; Sagare A; Satizabal CL; Schneider J; Seshadri S; Sur S; Tracy RP; Yasar S; Williams V; Singh H; Mazina L; Helmer KG; Corriveau RA; Schwab K; Kivisäkk P; Greenberg SM;
    Alzheimers Dement; 2021 Apr; 17(4):704-715. PubMed ID: 33480172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer's disease.
    Brosseron F; Traschütz A; Widmann CN; Kummer MP; Tacik P; Santarelli F; Jessen F; Heneka MT
    Alzheimers Res Ther; 2018 Feb; 10(1):25. PubMed ID: 29482610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders.
    Alcolea D; Clarimón J; Carmona-Iragui M; Illán-Gala I; Morenas-Rodríguez E; Barroeta I; Ribosa-Nogué R; Sala I; Sánchez-Saudinós MB; Videla L; Subirana A; Benejam B; Valldeneu S; Fernández S; Estellés T; Altuna M; Santos-Santos M; García-Losada L; Bejanin A; Pegueroles J; Montal V; Vilaplana E; Belbin O; Dols-Icardo O; Sirisi S; Querol-Vilaseca M; Cervera-Carles L; Muñoz L; Núñez R; Torres S; Camacho MV; Carrió I; Giménez S; Delaby C; Rojas-Garcia R; Turon-Sans J; Pagonabarraga J; Jiménez A; Blesa R; Fortea J; Lleó A
    Alzheimers Dement (N Y); 2019; 5():597-609. PubMed ID: 31650016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Study of Cerebrospinal Fluid microRNAs in Spinal Cord Injury and Neurodegenerative Diseases: Methodological Problems and Possible Solutions.
    Baichurina I; Valiullin V; James V; Rizvanov A; Mukhamedshina Y
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of proteomics in biomarker discovery in neurodegenerative diseases.
    Davidsson P; Sjögren M
    Dis Markers; 2005; 21(2):81-92. PubMed ID: 15920295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease.
    Milà-Alomà M; Suárez-Calvet M; Molinuevo JL
    Ther Adv Neurol Disord; 2019; 12():1756286419888819. PubMed ID: 31897088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases.
    Zerr I; Schmitz M; Karch A; Villar-Piqué A; Kanata E; Golanska E; Díaz-Lucena D; Karsanidou A; Hermann P; Knipper T; Goebel S; Varges D; Sklaviadis T; Sikorska B; Liberski PP; Santana I; Ferrer I; Zetterberg H; Blennow K; Calero O; Calero M; Ladogana A; Sánchez-Valle R; Baldeiras I; Llorens F
    Alzheimers Dement; 2018 Jun; 14(6):751-763. PubMed ID: 29391125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics.
    Kroksveen AC; Opsahl JA; Aye TT; Ulvik RJ; Berven FS
    J Proteomics; 2011 Apr; 74(4):371-88. PubMed ID: 21111852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker discovery in neurodegenerative diseases: a proteomic approach.
    Shi M; Caudle WM; Zhang J
    Neurobiol Dis; 2009 Aug; 35(2):157-64. PubMed ID: 18938247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead.
    Simrén J; Ashton NJ; Blennow K; Zetterberg H
    Curr Opin Neurobiol; 2020 Apr; 61():29-39. PubMed ID: 31838254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.